ArticleAlzheimer's & dementia (New York, N. Y.)2020
Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Article in Alzheimer's & dementia (New York, N. Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- TACR3 variant confers resilience to aging and Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026Article
- APOE ε4 as a predictor of cognitive decline and its interaction with hippocampal volume in Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.Neurology · 2025Article
- Genetic and Lifestyle Risks for Coronary Artery Disease and Long-Term Risk of Incident Dementia Subtypes.Circulation · 2025Article
- Unraveling the Complexity of Alzheimer's Disease: Insights into Etiology and Advancements in Treatment Strategies.Journal of molecular neuroscience : MN · 2025Review
- Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression.Brain, behavior, and immunity · 2024Article
- Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function.Brain and behavior · 2024Article
- The Impact of Apolipoprotein E (Biology · 2023Review
- Potential Modifying Effect of theInternational journal of molecular sciences · 2023Article
- Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer's Disease.Research square · 2023Article
- Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.European journal of clinical pharmacology · 2022Article
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.Nature reviews. Drug discovery · 2022Review
- Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?Therapeutic advances in chronic disease · 2022Review
- The Quick Dementia Rating System and Its Relationship to Biomarkers of Alzheimer's Disease and Neuropsychological Performance.Dementia and geriatric cognitive disorders · 2022Article
- Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- The predictive value of normal EEGs in dementia due to Alzheimer's disease.Annals of clinical and translational neurology · 2021Article
- The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Development of a Sex-Specific Risk Scoring System for the Prediction of Cognitively Normal People to Patients With Mild Cognitive Impairment (SRSS-CNMCI).Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
introductionPossession of the apolipoprotein E (
methodsThe "early AD" (ie, combined LMCI and mild AD) cohort of 649 subjects from J-ADNI and NA-ADNI were selected based on positivity of Aβ confirmed by amyloid positron emission tomography (PET) or cerebrospinal fluid testing. The rates of cognitive decline in the Mini Mental State Examination (MMSE), the Clinical Dementia Rating Sum of Boxes (CDR-SB), and the Alzheimer's Disease Assessment Scale-cognitive subscale 13 (ADAS-Cog) from baseline were examined using mixed-effects model. The effect of ε4 on time to conversion to dementia was also analyzed in LMCI using the Kaplan-Meier estimator and log-rank test.
resultsThe rates of cognitive decline were not significantly different between ε4 carriers and ε4 non-carriers in the total early AD cohort, which were affected neither by region nor by the number of ε4 alleles. In LMCI, ε4 carriers showed almost the same progression rates as ε4 non-carriers, except for a significantly faster decline in MMSE ( DISCUSSION: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.